Explore stories from Atlantic Canada.
Cooking Culinary Adventure: inspired by Halifax's Seaport Market | SaltWire #cooking #cookingshortsPARIS - Carmat, the artificial heart maker which this month got a 7 million euros lifeline to survive an imminent cash crunch, on Monday announced solid progress for its Aeson artificial heart device.
Carmat said it had performed seven Aeson implants as part of a clinical study in Paris and that it hoped to complete the study in 2025, in line with the company's targets. “This ramp-up is the result of growing experience in patient selection and attests to the steep learning curve of the surgical procedure,” said Professor Christian Latremouille, Director of Surgical Affairs at Carmat, in a press release.
The clinical study, called EFICAS, is a prospective study designed to include 52 patients eligible for transplants, currently enrolled by a network of six French cardiology centers, Carmat said. The primary objective of the study is 180-day post-implantation survival without disabling stroke or successful heart transplant within 180 days of implantation, the company said.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Stonepeak to take shipping-container lessor Textainer private in $2.1 billion dealExplore stories from Atlantic Canada.
Lire la suite »
Philippines tells China to stop provocative actions in South China SeaExplore stories from Atlantic Canada.
Lire la suite »
Motor racing-Sargeant ends a 30-year wait for US driver to score in F1Explore stories from Atlantic Canada.
Lire la suite »
Philippines tells China to stop provocative actions in South China SeaExplore stories from Atlantic Canada.
Lire la suite »
Toyota lobbies India to cut hybrid-car taxes as much as 21%Explore stories from Atlantic Canada.
Lire la suite »